small sized icon representing the Cardiovascular area of interest
Cardiovascular
GME:X Logo
GME:X
medium sized icon representing the Diabetes Care area of interest
Diabetes Care
small sized icon representing the Radiology area of interest
Radiology
small sized icon representing the Oncology area of interest
Oncology
small sized icon representing the Ophthalmology area of interest
Ophthalmology
small sized icon representing the Women's Health area of interest
Women's Health
medium sized icon representing the Nephrology area of interest
Nephrology
Bayer MedLearnEducate, Innovate & Heal
Podcast

Dr Javed Butler: Worsening Heart Failure

Dr. Javed Butler discusses the critical issue of worsening heart failure. He describes it as a progression where patients, initially stabilized on optimal medical therapy, experience gradual declines in symptoms like fatigue and breathlessness, often requiring adjustments in medications like diuretics. This deterioration significantly worsens prognosis, leading to higher mortality and readmission rates, especially after hospitalization. 

Our speakers

  • MD, MPH, MBA, Baylor Scott and White Health.

    Dr. Javed Butler is a prominent figure in cardiovascular medicine, especially known for his work on heart failure. Based in Dallas, Texas, he holds leadership positions at Baylor Scott & White, including the Maxwell A. and Gayle H. Clampitt Endowed Chair, president, and chief research executive at the Research Institute, and senior vice president at the Health system. His expertise is recognized by his fellowships in several prestigious organizations, such as the Heart Failure Society of America, the European Society of Cardiology, the American College of Cardiology, and the American Heart Association.

Related content
Dr Javed Butler: Vericiguat in Heart Failure
PP-VER-IN-0231-1, September 2024
Dr Javed Butler: Initiating vericiguat
PP-VER-IN-0232-1, September 2024
Dr Javed Butler: Vericiguat: RRR vs. ARR
Why is considering ARR so important while we look at clinical trial data
PP-VER-IN-0233-1, September 2024